- Home
- GXAI vs CURX Comparison
GXAI vs CURX Comparison
Compare GXAI & CURX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GXAI | CURX |
|---|---|---|
| Founded | 2021 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 9.4M |
| IPO Year | 2022 | 2024 |
Fundamental Metrics
Financial Performance| Metric | GXAI | CURX |
|---|---|---|
| Price | $0.77 | $4.94 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.8M | 139.1K |
| Earning Date | 05-14-2026 | 09-09-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.35 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,933,030.00 | N/A |
| Revenue This Year | $271.23 | N/A |
| Revenue Next Year | $36.32 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 47901.74 | N/A |
| 52 Week Low | $0.73 | $0.18 |
| 52 Week High | $2.63 | $9.18 |
Technical Indicators
Market Signals| Indicator | GXAI | CURX |
|---|---|---|
| Relative Strength Index (RSI) | 42.16 | 80.48 |
| Support Level | $0.75 | $0.33 |
| Resistance Level | $1.30 | $6.00 |
| Average True Range (ATR) | 0.06 | 0.40 |
| MACD | -0.00 | 0.15 |
| Stochastic Oscillator | 8.30 | 80.16 |
Price Performance
Historical ComparisonAbout GXAI Gaxos.ai Inc.
Gaxos.AI Inc is a technology company focused on reshaping the way people interact with artificial intelligence across everyday life and high-impact industries. It is engaged in building a portfolio of AI-powered solutions designed to make advanced technology more practical, accessible, and transformative. The company's portfolio spans defense, health and wellness, entertainment, and productivity - bringing intelligent tools to markets where innovation can drive meaningful real-world outcomes. It operates as a single operating segment technology-based company that is developing applications aimed at redefining the way it utilizes artificial intelligence (AI) to optimize the user experience.
About CURX Curanex Pharmaceuticals Inc
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant.